Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ramcon to become Scandinavian distributor for ID Tag RVP (respiratory viral panel):

This article was originally published in Clinica

Executive Summary

Danish diagnostics product distributor Ramcon is to become exclusive distributor of the ID-Tag respiratory viral panel (RVP), developed by Canada's Tm Bioscience, in Denmark, Sweden, Finland and Norway. The ID-Tag RVP detects 20 respiratory viruses and subtypes, including avian flu and SARS, and runs on Luminex analysers, which Birkerod-based Ramcon also distribute across Scandinavia, said Tm Bioscience. The Toronto, Ontario firm has also secured distribution agreements for the test in the Netherlands and Turkey and said it plans to continue increasing its commercial distribution footprint across Europe in anticipation of regulatory approval - including FDA 510(k) clearance, Canadian approval and European CE-marking - of the product.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT052367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel